Claris Lifesciences
1
20M
1
0.04
- Areas of investment
Summary
Claris Lifesciences is the famous Corporate Investor, which was founded in 1994. The company was established in Asia in India. The main office of represented Corporate Investor is situated in the Ahmedabad.
The fund is generally included in less than 2 deals every year. The usual things for fund are deals in the range of 10 - 50 millions dollars. The top activity for fund was in 2008.
The usual cause for the fund is to invest in rounds with more than 10 partakers. Despite the Claris Lifesciences, startups are often financed by Wellington Partners, Sanderling Ventures, Index Ventures. The meaningful sponsors for the fund in investment in the same round are Scott Harkonen, Sanderling Ventures, Robin J. Cook.
Among the most popular portfolio startups of the fund, we may highlight CoMentis. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. We can highlight the next thriving fund investment areas, such as Health Care, Biotechnology. For fund there is no match between the location of its establishment and the land of its numerous investments - United States.
Investments analytics
Analytics
- Total investments
- 1
- Lead investments
- 0
- Rounds per year
- 0.04
- Investments by industry
- Biotechnology (1)
- Medical (1)
- Health Care (1)
- Investments by region
-
- United States (1)
- Peak activity year
- 2008
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 17
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.